Daniel Lysák

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 351 citations

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Paolo Ghia, Andrzej Pluta, Małgorzata Wach et al. · HemaSphere · 2022 · 95 citations · Full text

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak et al. · New England Journal of Medicine · 2025 · 65 citations

Proteomic profiling of blood‐dialyzer interactome reveals involvement of lectin complement pathway in hemodialysis‐induced inflammatory response

Jan Mareš, Pavlína Richtrová, Alena Hricinova et al. · PROTEOMICS - CLINICAL APPLICATIONS · 2010 · 56 citations